Breaking News

First Patient Dosed in Melanoma Vaccine Candidate Study With Checkpoint Inhibitors

December 23, 2020 • 4:10 pm CST
(Precision Vaccinations News)

Copenhagen-based Evaxion Biotech announced the dosing of the first patient in a Phase I/IIa clinical trial of its adjuvant immunotherapy EVX-02, combined with checkpoint inhibitors in patients who have had a complete resection of Stage IIIB/IIIC/IIID or Stage IV melanoma and are at high risk of recurrence. The study is planned to take place at five clinical centers in Australia. Early data readout from this study is expected in H1 2021.

Lars Wegner, CEO of Evaxion Biotech, stated in a press release issued on December 23, 2020, “We are very excited to start this Phase I/IIa study with EVX-02 further demonstrating the potential of Evaxion’s integrated PIONEERTM artificial intelligence platform to accelerate the discovery and development of a new generation of patient-specific cancer immunotherapies."

"We believe that the computational power behind the discovery of this compound shows that EVX-02 may have the potential to make a difference in malignant melanoma, which accounts for 1% of skin tumors and causes of 60% mortality due to skin cancers.”

Medical Review by

Our Trust Standards: Medical Advisory Committee

Share